BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sekiguchi F, Kawabata A. Role of HMGB1 in Chemotherapy-Induced Peripheral Neuropathy. Int J Mol Sci 2020;22:E367. [PMID: 33396481 DOI: 10.3390/ijms22010367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Tsubota M, Miyazaki T, Ikeda Y, Hayashi Y, Aokiba Y, Tomita S, Sekiguchi F, Wang D, Nishibori M, Kawabata A. Caspase-Dependent HMGB1 Release from Macrophages Participates in Peripheral Neuropathy Caused by Bortezomib, a Proteasome-Inhibiting Chemotherapeutic Agent, in Mice. Cells 2021;10:2550. [PMID: 34685531 DOI: 10.3390/cells10102550] [Reference Citation Analysis]
2 Domoto R, Sekiguchi F, Tsubota M, Kawabata A. Macrophage as a Peripheral Pain Regulator. Cells 2021;10:1881. [PMID: 34440650 DOI: 10.3390/cells10081881] [Reference Citation Analysis]
3 Miyamoto T, Domoto R, Sekiguchi F, Kamaguchi R, Nishimura R, Matsuno M, Tsubota M, Fujitani M, Hatanaka S, Koizumi Y, Wang D, Nishibori M, Kawabata A. Development of hepatic impairment aggravates chemotherapy-induced peripheral neuropathy following oxaliplatin treatment: Evidence from clinical and preclinical studies. Journal of Pharmacological Sciences 2022. [DOI: 10.1016/j.jphs.2022.01.006] [Reference Citation Analysis]
4 Meng L, Huang J, Qiu F, Shan X, Chen L, Sun S, Wang Y, Yang J. Peripheral Neuropathy During Concomitant Administration of Proteasome Inhibitors and Factor Xa Inhibitors: Identifying the Likelihood of Drug-Drug Interactions. Front Pharmacol 2022;13:757415. [DOI: 10.3389/fphar.2022.757415] [Reference Citation Analysis]
5 Yardim A, Gur C, Comakli S, Ozdemir S, Kucukler S, Celik H, Kandemir FM. Investigation of the effects of berberine on bortezomib-induced sciatic nerve and spinal cord damage in rats through pathways involved in oxidative stress and neuro-inflammation. Neurotoxicology 2022:S0161-813X(22)00019-5. [PMID: 35121005 DOI: 10.1016/j.neuro.2022.01.011] [Reference Citation Analysis]
6 Hiramoto S, Asano H, Miyamoto T, Takegami M, Kawabata A. Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan. PLoS One 2021;16:e0261473. [PMID: 34972132 DOI: 10.1371/journal.pone.0261473] [Reference Citation Analysis]
7 Domoto R, Sekiguchi F, Kamaguchi R, Iemura M, Yamanishi H, Tsubota M, Wang D, Nishibori M, Kawabata A. Role of neuron-derived ATP in paclitaxel-induced HMGB1 release from macrophages and peripheral neuropathy. J Pharmacol Sci 2022;148:156-61. [PMID: 34924121 DOI: 10.1016/j.jphs.2021.11.003] [Reference Citation Analysis]